If You Can't Make Your Drug a Blockbuster, Sue Your Competitor

Amarin sues AstraZeneca over its fish oil pill Epanova. If the companies can't reach sales close to GlaxoSmithKline's Lovaza, it will be for naught.

Mar 4, 2014 at 5:34PM

Amarin's (NASDAQ:AMRN) lawyers sure are keeping busy.

The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded approval to treat patients with moderately high triglyceride levels while waiting for an outcomes study in that population. The FDA pulled the SPA because it now wants to see the results of the outcomes study to confirm Vascepa is not only lowering triglyceride levels, but also reducing heart attacks and strokes.

Amarin is also suing the FDA over the agency's decision to only give Vascepa three years of exclusivity rather than designating it as a New Chemical Entity, which would entitle the drug to five years of exclusivity. Vascepa is a purified fish oil, but the FDA apparently decided that it wasn't different enough from GlaxoSmithKline's (NYSE:GSK) Lovaza to justify designating it as a New Chemical Entity.

Vascepa

Source: Amarin

And today the company announced it's suing AstraZeneca (NYSE:AZN) over its fish oil pill Epanova. The pharma giant acquired the drug when it purchased Omthera Pharmaceuticals last year. Amarin claims that its patent covers "lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA [eicosapentaenoic acid] as free acid, and no more than about 30% DHA [docosahexaenoic acid]."

EPA and DHA are two types of omega3 fatty acids found in fish oils. Amarin developed Vascepa as purified EPA because there's a hypothesis that DHA may actually increase bad LDL cholesterol. DHA makes up about 45% of the omega3 fatty acids in GlaxoSmithKline's Lovaza, and the drug increased LDL cholesterol by 44% in the pivotal study used to approve the drug. Vascepa on the other hand, lowered LDL cholesterol by 5%.

As best I can tell -- there's less info on Epanova because it's not approved yet -- AstraZeneca's drug fits the definition that Amarin claims to have covered. The bigger question is whether the patent is valid. In general, method of use patents like this one are a lot harder to defend than composition of matter patents.

Even if the chance for a positive outcome of each lawsuit/appeal is relatively low, it's probably worth whatever Amarin is paying the lawyers. Of course, the return on investment depends on sales of Vascepa and Epanova. Amarin has struggled to gain traction with Vascepa, selling just $10 million worth of the drug in the fourth quarter. If AstraZeneca has similar problems marketing Epanova, blocking or trying to gain a royalty on the drug won't be worth much to Amarin.

These six companies have more potential than Amarin
Fool co-founder David Gardner has a scientific approach to crushing the market. He's carefully chosen six picks for ultimate growth instantly that you can see in this premium report free for you today. Click here now for access.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers